{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:01Z","timestamp":1788869341327,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cllc.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:54:46Z","timestamp":1783007686000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Sequencing Completion and Timeliness Using a Reflex Testing Protocol for Patients with Stage II to IV Nonsquamous Non\u2013Small Cell Lung Cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Gordon","family":"Smilnak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Stelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debamita","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-6677","authenticated-orcid":false,"given":"Ryan D.","family":"Gentzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.06.012_bib0001","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2026.06.012_bib0002","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMp2210638","article-title":"Closing the gap in cancer genomic testing","volume":"387","author":"Schilsky","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0003","doi-asserted-by":"crossref","first-page":"e951","DOI":"10.1200\/OP.22.00817","article-title":"Closing the testing gap: standardization of comprehensive biomarker testing for metastatic non-small-cell lung cancer in a large community oncology practice","volume":"19","author":"Waterhouse","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.cllc.2026.06.012_bib0004","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/OP.24.00070","article-title":"Electronic medical record-based nudge intervention to increase comprehensive molecular genotyping in patients with metastatic non-small cell lung cancer: results from a prospective clinical trial","volume":"20","author":"Marmarelis","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.cllc.2026.06.012_bib0005","article-title":"Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non-small-cell lung cancer","volume":"7","author":"Aggarwal","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0007","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0008","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non-small cell lung cancer: TRUST","volume":"43","author":"Perol","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0009","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0010","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF (V600)-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0011","first-page":"981","article-title":"The potential long-term comparative effectiveness of larotrectinib and entrectinib for second-line treatment of TRK fusion-positive metastatic lung cancer","volume":"26","author":"Roth","year":"2020","journal-title":"J Manag Care Spec Ph"},{"key":"10.1016\/j.cllc.2026.06.012_bib0012","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.06.012_bib0013","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0014","unstructured":"National Comprehensive Cancer Network, Non-small Cell Lung Cancer (Version 6.2026). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf, 2026 (accessed 16 July 2026)."},{"key":"10.1016\/j.cllc.2026.06.012_bib0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0016","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2602628","article-title":"Selpercatinib in early-stage RET fusion-positive non-small-cell lung cancer","author":"Wu","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0019","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0021","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0022","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cllc.2023.03.002","article-title":"Real-world biomarker testing patterns in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in a US community-based oncology practice setting","volume":"24","author":"Sireci","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.06.012_bib0023","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.06.012_bib0024","doi-asserted-by":"crossref","first-page":"461","DOI":"10.6004\/jnccn.2025.7063","article-title":"Molecular biomarker testing patterns and turnaround time in US patients with advanced non-small cell lung cancer","volume":"23","author":"Wang","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2026.06.012_bib0025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jmoldx.2025.02.001","article-title":"Impact and reproducibility of in-house targeted next-generation sequencing biomarker testing in non-small-cell lung cancer: an Italian multi-institutional experience","volume":"27","author":"Rapa","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cllc.2026.06.012_bib0026","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.3390\/cancers16213654","article-title":"The impact of next-generation sequencing workflows on outcomes in advanced lung cancer: a retrospective analysis at one academic health system","volume":"16","author":"Vakkalagadda","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.06.012_bib0027","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1016\/j.jtho.2024.05.202","article-title":"Real-world patient characteristics, biomarker testing, and adjuvant therapy for resected NSCLC at US Oncology Clinics, 2019-2023","volume":"19","author":"Hu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0028","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12931-023-02321-9","article-title":"Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study","volume":"24","author":"Fintelmann","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.cllc.2026.06.012_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jasc.2025.03.005","article-title":"Optimizing tissue adequacy for next-generation sequencing in small biopsies and fine-needle aspirations for nonsmall cell lung cancer: a root cause analysis and proposed solutions","volume":"14","author":"Ding","year":"2025","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0031","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1002\/cncr.34926","article-title":"The American Cancer Society National Lung Cancer roundtable strategic plan: methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer","volume":"130","author":"Roy-Chowdhuri","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2026.06.012_bib0032","article-title":"Metastatic NSCLCs with limited tissues: how to effectively identify driver alterations to guide targeted therapy in Chinese patients","volume":"2","author":"Li","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.06.012_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6886","article-title":"Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: experience at a tertiary academic institution in Canada","volume":"13","author":"Grafham","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.cllc.2026.06.012_bib0034","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.molonc.2015.05.004","article-title":"Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS)","volume":"9","author":"Al-Kateb","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0035","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cancers7030859","article-title":"Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies","volume":"7","author":"Chen","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.06.012_bib0036","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jmoldx.2013.05.004","article-title":"Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens","volume":"15","author":"Spencer","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cllc.2026.06.012_bib0037","doi-asserted-by":"crossref","first-page":"S685","DOI":"10.1016\/j.jtho.2025.09.1309","article-title":"EP.06.15 reflex next generation sequencing testing in NSCLC: overcoming barriers to equitable molecular profiling in an urban healthcare network","volume":"20","author":"Provenzano BG","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0038","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/curroncol29030113","article-title":"Point of care molecular testing: community-based rapid next-generation sequencing to support cancer care","volume":"29","author":"Sheffield","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0039","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/j.jtho.2024.09.885","article-title":"EP.04E.08 rapid in house next generation sequencing and impact on treatment decisions and initiation in advanced NSCLC","volume":"19","author":"Kang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0040","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.21037\/tlcr-21-570","article-title":"Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience","volume":"10","author":"Zacharias","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2026.06.012_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002560","article-title":"The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study","volume":"3","author":"Boch","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.cllc.2026.06.012_bib0042","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.06.012_bib0043","doi-asserted-by":"crossref","first-page":"934","DOI":"10.6004\/jnccn.2023.7039","article-title":"Biomarker testing, treatment, and outcomes in patients with advanced\/metastatic non-small cell lung cancer using a real-world database","volume":"21","author":"Bhandari","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.cllc.2026.06.012_bib0044","article-title":"Real-world impact of comprehensive genomic profiling on biomarker detection, receipt of therapy, and clinical outcomes in advanced non-small cell lung cancer","volume":"8","author":"Wallenta Law","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0045","article-title":"Plasma genotyping at the time of diagnostic tissue biopsy decreases time-to-treatment in patients with advanced NSCLC-results from a prospective pilot study","volume":"3","author":"Thompson","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.06.012_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.42970","article-title":"Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer","volume":"7","author":"Owen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cllc.2026.06.012_bib0047","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jtho.2020.01.019","article-title":"Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing","volume":"15","author":"Cohen","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0048","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"Janne","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.06.012_bib0049","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12916-021-02207-x","article-title":"Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study","volume":"20","author":"Zou","year":"2022","journal-title":"BMC Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:19:48Z","timestamp":1788866388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525730426000926"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.06.012","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-Generation Sequencing Completion and Timeliness Using a Reflex Testing Protocol for Patients with Stage II to IV Nonsquamous Non\u2013Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}